KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Arbutus Biopharma (ABUS) Accumulated Depreciation & Amortization (2016 - 2025)

Arbutus Biopharma's Accumulated Depreciation & Amortization history spans 15 years, with the latest figure at $352000.0 for Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization fell 66.38% year-over-year to $352000.0; the TTM value through Sep 2025 reached $352000.0, down 66.38%, while the annual FY2024 figure was $13.0 million, 9.21% up from the prior year.
  • Accumulated Depreciation & Amortization for Q3 2025 was $352000.0 at Arbutus Biopharma, up from $341000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $13.0 million in Q4 2024 and bottomed at $330000.0 in Q1 2025.
  • The 5-year median for Accumulated Depreciation & Amortization is $777000.0 (2022), against an average of $2.9 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization rose 23.0% in 2021 before it crashed 66.38% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $9.4 million in 2021, then rose by 15.22% to $10.8 million in 2022, then increased by 10.17% to $11.9 million in 2023, then rose by 9.21% to $13.0 million in 2024, then plummeted by 97.29% to $352000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Accumulated Depreciation & Amortization are $352000.0 (Q3 2025), $341000.0 (Q2 2025), and $330000.0 (Q1 2025).